Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | KDM4B | O94953 | 1/20 | 0.43 |
| ▸ | KDM5C | P41229 | 1/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MGMT | P16455 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19064637 | 0.81 | SMN1; SMN2 (0.51) | SMN1; SMN2HIF1AADORA3CYP1A2TSHR | |
| SCHEMBL17009422 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2HIF1AADORA3CYP1A2TSHR | |
| SCHEMBL22892316 | 0.77 | ADORA3 (0.38) | SMN1; SMN2HIF1AADORA3CYP1A2TSHR | |
| SCHEMBL17009436 | 0.76 | GAA (0.43) | SMN1; SMN2HIF1AADORA3CYP1A2TSHR | |
| Kinetin SCHEMBL29829493 | 0.76 | SMN1; SMN2 (0.66) | SMN1; SMN2HIF1AADORA3CYP1A2TSHR | |
| Kinetin SCHEMBL15705 | 0.76 | SMN1; SMN2 (0.66) | SMN1; SMN2HIF1AADORA3CYP1A2TSHR | |
| SCHEMBL19958904 | 0.75 | SMN1; SMN2 (0.42) | SMN1; SMN2HIF1AADORA3CYP1A2TSHR | |
| SCHEMBL5808902 | 0.75 | SMN1; SMN2 (0.42) | SMN1; SMN2HIF1AADORA3CYP1A2TSHR | |
| SCHEMBL15950879 | 0.73 | MAPT (0.51) | HIF1ACYP1A2TSHRMEN1TP53 | |
| SCHEMBL22785768 | 0.72 | CYP3A4 (0.36) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274989-A9 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | MITOKININ, INC. (US) | 2022-09-01 | — | — | US | disclosed |
| US-20210107910-A1 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | MITOKININ, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-20210107910-A1 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | MITOKININ, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| EP-2953950-B1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | UNIV CALIFORNIA (US) | 2021-01-13 | — | — | EP | disclosed |
| US-10851109-B2 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | MITOKININ LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851109-B2 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | MITOKININ LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200283442-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | MITOKININ, INC. | 2020-09-10 | — | — | US | disclosed |
| US-10723737-B2 | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190194207-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ INC (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194207-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ INC (US) | 2019-06-27 | — | — | US | disclosed |
| US-10167286-B2 | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease | MITOKININ, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180072731-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | MITOKININ, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180072731-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | MITOKININ, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20170190704-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | Mitokinin, LLC (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190704-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | Mitokinin, LLC (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190704-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | Mitokinin, LLC (US) | 2017-07-06 | — | — | US | disclosed |
| US-20160108044-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | MITOKININ, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160108044-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | MITOKININ, INC. | 2016-04-21 | — | — | US | disclosed |
| WO-2015123365-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ LLC (US) | 2015-08-20 | — | — | WO | disclosed |
| WO-2014124458-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072731-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | PINK1, CKMT1A; CKMT1B, NLN | SMN1; SMN2 8/4885HIF1A 2267/4885ADORA3 3705/4885 |
| US-10723737-B2 | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | PINK1, CKMT1A; CKMT1B, NLN | SMN1; SMN2 8/4885HIF1A 2267/4885ADORA3 3705/4885 |
| US-20210107910-A1 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | NLN, NME4, COQ8A | SMN1; SMN2 106/4885HIF1A 3407/4885ADORA3 667/4885 |
| US-20160108044-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | PINK1, CKMT1A; CKMT1B, NLN | SMN1; SMN2 8/4885HIF1A 2267/4885ADORA3 3705/4885 |
| US-20190194207-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, HAGH, PDF | SMN1; SMN2 7/4885HIF1A 1911/4885ADORA3 3956/4885 |
| US-10167286-B2 | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease | NLN, NME4, COQ8A | SMN1; SMN2 105/4885HIF1A 3561/4885ADORA3 557/4885 |
| US-20220274989-A9 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | NLN, NME4, COQ8A | SMN1; SMN2 106/4885HIF1A 3407/4885ADORA3 667/4885 |
| US-10851109-B2 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | NLN, NME4, COQ8A | SMN1; SMN2 106/4885HIF1A 3407/4885ADORA3 667/4885 |
| US-20200283442-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | SNCA, SMN1; SMN2, CLN6 | SMN1; SMN2 2/4885HIF1A 1240/4885ADORA3 3802/4885 |
| US-20170190704-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, HAGH, MT-ND2 | SMN1; SMN2 87/4885HIF1A 2711/4885ADORA3 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.